ONO-1110 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder (MDD
Conditions
Major Depressive Disorder (MDD
Trial Timeline
Jan 16, 2025 → Aug 31, 2026
NCT ID
NCT06792136About ONO-1110 + Placebo
ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Major Depressive Disorder (MDD. The current trial status is active. This product is registered under clinical trial identifier NCT06792136. Target conditions include Major Depressive Disorder (MDD.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06752603 | Phase 2 | Recruiting |
| NCT06752590 | Phase 2 | Recruiting |
| NCT06708416 | Phase 2 | Active |
| NCT06805565 | Phase 2 | Active |
| NCT06792136 | Phase 2 | Active |
Competing Products
20 competing products in Major Depressive Disorder (MDD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 33 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |